Search Results

Genetown

Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology

Elektrofi, Inc. announced that it has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company.

January 3, 2024

·

2 min read

Press Releases

Elektrofi Announces Oversubscribed $112.25 Million Series C Financing to Establish Commercial-Scale GMP Manufacturing Capacity & Accelerate Clinical Development Across its Growing Portfolio of Partnered Programs

November 1, 2024

·

2 min read

Genetown

Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement

Elektrofi, Inc. announced that it has entered a multi-target research collaboration and license agreement with Eli Lilly and Company to develop next-generation medicines that can be delivered subcutaneously.

October 24, 2023

·

2 min read

Business

Elektrofi Appoints Victoria Sluzky as Chief Technology Officer to Drive Innovation and Technical Excellence

Elektrofi, a biopharmaceutical formulation technology company focused on leveraging strategic partnerships to revolutionize the delivery of biologic therapies, appointed Victoria Sluzky as Chief Technology Officer.

July 17, 2023

·

3 min read

Business

Elektrofi Announces Collaboration with Thermo Fisher Scientific to Strengthen Manufacturing Capabilities for Future Clinical Trials

Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi’s breakthrough ultra-high concentration subcutaneous products.

February 7, 2023

·

2 min read

Genetown

Elektrofi Raises $40 Million Financing to Establish GMP Manufacturing Capabilities for Upcoming Clinical Studies and Expand Development Pipeline

Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, announced the completion of a $40 million Series B financing round.

June 13, 2022

·

2 min read

Genetown

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

Elektrofi & IPA announced they are entering into a collaboration to explore a high-concentration formulation of IPA’s COVID-19 antibody cocktail, PolyTope® TATX-03.

March 14, 2022

·

7 min read

Business

Elektrofi Enters Global Collaboration and License Agreement with argenx to Explore New Subcutaneous Product Formulations

The agreement provides argenx access to Elektrofi’s breakthrough high-concentration, low-volume delivery technology for the development of therapeutic products

April 20, 2021

·

2 min read

Genetown

Elektrofi Receives Contract Under the Defense Health Agency SBIR/STTR Program to Advance Antibody Delivery Formulations for the Treatment of Covid-19 and Future Pandemics

Elektrofi announced it has entered into a contract with the Defense Health Agency Small Business Innovation Research Program within the Department of Defense focused on exploring the company’s platform formulation technology for the delivery of prefilled, high-dose formulations for the rapid deployment of antibody treatments for COVID-19 and pandemic preparation.

February 28, 2022

·

3 min read

Business

Elektrofi and Takeda Pharmaceutical Company Enter into an Evaluation Agreement on Elektrofi’s Formulation Technology

Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced it has entered into an evaluation agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the potential use of the company’s high concentration delivery technology

September 21, 2020

·

2 min read